JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.Appearance:SolidIC50& Target:JAK1 26 nM (IC 50 ) JAK2 0.7 nM (IC 50 ) JAK3 39 nM (IC 50 ) FLT3 4 nM (IC 50 )In Vitro:JAK2/FLT3-IN-1 (0.008-1 μM; for 2 hours) (TFA) down-regulates p-FLT3 in a dose-dependent manner. JAK2/FLT3-IN-1 (5-100 nM; for 2 hours) (TFA) has a dose-dependent effect on the induction of apoptosis in the MV4-11 cells. JAK2/FLT3-IN-1 (5-100 nMIn Vivo:JAK2/FLT3-IN-1 (30 and 60mg/kg/day; p.o.; for 14 days) (TFA) exhibits significant antitumor effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NOD/SCID mouse modelsDosage: 30 aBiological Activity:JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. Molecular Formula: C27H35F4N7O3 Molecular Weight: 581.61
- UPC:
- 51111756
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- J658941-5mg
- Product Size:
- 5mg
